dgkh000444
10.3205/dgkh000444
urn:nbn:de:0183-dgkh0004449
Review Article
Candida auris: a novel emerging nosocomial pathogen – properties, epidemiological situation and infection control
Candida auris: ein neuer gefährlicher nosokomialer Erreger – Eigenschaften, epidemiologische Situation und Prävention
Caliman Sato
Caliman Sato
Marcelo
M
Center for Lasers and Applications, Instituto de Pesquisas Energéticas e Nucleares (IPEN-CNEN), São Paulo, Brazil
author
Izu Nakamura Pietro
Izu Nakamura Pietro
Emilene Cristine
EC
Bauru State Hospital, Bauru, São Paulo, Brazil
author
Marques da Costa Alves
Marques da Costa Alves
Lucas
L
Bauru State Hospital, Bauru, São Paulo, Brazil
author
Kramer
Kramer
Axel
A
Institute of Hygiene and Environmental Medicine, University Medicine Greifswald, Greifswald, Germany
author
da Silva Santos
da Silva Santos
Paulo Sérgio
PS
Prof. Dr.
Al. Dr. Octávio Pinheiro Brisolla, 9-75, Vila Universitária, Bauru – SP, Brazil, Zip Code – 17012-901, Phone: +55 14 32266113Bauru School of Dentistry of University of São Paulo, Bauru, São Paulo, Brazil
paulosss@fob.usp.br
author
German Medical Science GMS Publishing House
Düsseldorf
610
2023081620230927
engl
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).
2196-5226
18
GMS Hygiene and Infection Control
GMS Hyg Infect Control
18
20230927Correction of the article type
Immunsuppression und kritische Erkrankungen öffnen in Kombination mit einem ökologischen Ungleichgewicht die Tür für neuartige Infektionen durch opportunistische Pilze wie im Fall von Candida (C). auris. C. auris, einem multiresistentem Hefepilz. C. auris hat sich weltweit ausgebreitet und kann Infektionen und Ausbrüche in Gesundheitseinrichtungen verursachen. In dem narrativen Review werden die Eigenschaften des Erregers, die Entwicklung der epidemiologischen Situation, die nosokomiale Ausbreitung und die Ursachen für nosokomiale Ausbrüche, die durch C. auris im Krankenhausumfeld getriggert werden, erörtert, internationale Empfehlungen zur Infektionskontrolle zusammengefasst und ergänzende Hinweise zu Diagnostik, Screening und Antibiotic Stewardship gegeben.
Immunosuppression and critical illnesses in combination with ecological imbalance open the door for novel opportunistic fungal infections, as in case of Candida (C). auris. C. auris has emerged globally as a multidrug-resistant yeast, causing infections and outbreaks in health care facilities. This narrative review discusses the properties of the yeast, the development of the epidemiological situation, the nosocomial spread and causes for nosocomial outbreaks triggered by C. auris in the hospital environment, and summarizes international recommendations for infection control, supplemented by suggestions on diagnostic, screening and antibiotic stewardship.
Epidemiologic developmentCandida (C.) auris was first described as causative agent of otomycosis in Japan in 2009 . The clonal spread of C. auris has now reached Middle East, Africa, South America, North America and Europe, posing a severe global health hazard . In the period from 2013 to 2017, 620 detections of C. auris were reported in Europe, of which 24.8% involved infection . In Germany, only a few (mostly introduced) cases have been reported so far . The Pan American Health Organization/World Health Organization (PAHO/WHO) issued an epidemiological alert in October 2016 in response to reports of C. auris outbreaks in Latin American healthcare facilities . The high rate of transmissibility and mortality, which ranged from 30 to 60% of persons afflicted, prompted the alert. The first major epidemic in Latin America occurred in Venezuela in 2013 at an intensive care unit of a tertiary care hospital in Maracaibo. The outbreak affected <![CDATA[18 individuals</PlainText></TextGroup>, 13 of whom were children, with a 28% case fatality rate <TextLink reference="5"></TextLink>. Three years later, in 2015, the world’s worst outbreak occurred in London, affecting 50 patients in one hospital; 22 were infected and 28 were colonized <TextLink reference="6"></TextLink>. Resulting a systematic study and global meta-analysis covering a decade, more than 4,000 cases of <Mark2>C. auris</Mark2> were reported from at least 33 countries with high resistance to fluconazole, moderate resistance to amphotericin B and caspofungin, high sensitivity to micafungin and anidulafungin, and a mortality rate of 45% in cases of disseminated infections <TextLink reference="7"></TextLink>. According to a 2020 study, <Mark2>C. auris</Mark2> is now established in 43 countries across five continents (Australia, Bangladesh, Canada, China, Colombia, France, Germany, India, Israel, Japan, Kenya, Kuwait, Malaysia, Netherlands, Oman, Pakistan, Panama, Qatar, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sudan, Switzerland, United Kingdom, United States, Venezuela, Austria, Belgium, Chile, Costa Rica, Egypt, Greece, Italy, Iran, Mexico, Norway, Poland, Taiwan, Thailand, United Arab Emirates). In 2022 were 2,377 clinical cases and 5,754 screening cases <TextLink reference="8"></TextLink>. </Pgraph><Pgraph><Mark2>C. auris</Mark2> is an example of the consequences of uncontrolled ecology increased by the Coronavirus pandemic. With the rise in COVID-19 infections, a trend of bacterial, fungal, and viral superinfection has been noted. Due to the multidrug-resistance and easy transmissibility, <TextGroup><Mark2>C. auris</Mark2></TextGroup> is difficult to manage in COVID-positive patients <TextLink reference="9"></TextLink>. The first case of <Mark2>C. auris</Mark2> from Brazil (strain I) was published in 2021 <TextLink reference="10"></TextLink>. Despite the fact that the microorganism was isolated from a catheter from an adult patient in an intensiv care unit (ICU) in Salvador, Bahia state, Brazil, due to COVID-19 complications, the first confirmation of this microorganism occurred only on <TextGroup><PlainText>December 07</PlainText></TextGroup>, 2020, despite the fact that the patient was not contaminated <TextLink reference="10"></TextLink>. </Pgraph></TextBlock>
<TextBlock linked="yes" name="Characteristics of C. auris">
<MainHeadline>Characteristics of C. auris</MainHeadline><SubHeadline>Phylogenetic analysis</SubHeadline><Pgraph>Initial phylogenetic analysis of <Mark2>C. auris</Mark2> revealed four populations named after the geographical location South Asia, East Asia, Africa, and South America (clade I, II, III and IV, respectively) <TextLink reference="11"></TextLink>, <TextLink reference="12"></TextLink>, that corresponded to these geographical regions <TextLink reference="5"></TextLink>. Most strains showed phylogeographic mixing; strain IV with isolates primarily from South America showed the strongest phylogeography <TextLink reference="5"></TextLink>. In the meantime, whole genome sequencing (WGS) analysis confirmed the existence of a fifth clade by providing WGS data of another four Iranian isolates <TextLink reference="13"></TextLink>. </Pgraph><SubHeadline>Pathopotency</SubHeadline><Pgraph><Mark2>C. auris</Mark2> was named after the first case of otomycosis and is derived from the Latin word for ear (auris). However, despite the name, <Mark2>C. auris</Mark2> colonizes asymptomatically on mucous membranes (nose, throat), is detectable on the skin (axilla, ear, inguinal area), in wounds, respiratory samples and stool as well as urine, and is a pathogen of invasive infections such as that of the bloodstream <TextLink reference="5"></TextLink> and urinary tract <TextLink reference="14"></TextLink>. Asymptomatic colonization represents a risk for <Mark2>C. auris</Mark2> transmission. The future significance for oropharyngeal infections cannot yet be assessed <TextLink reference="15"></TextLink>. </Pgraph><Pgraph>The ANVISA Technical Standard (Agência Nacional de <TextGroup><PlainText>Vigilância</PlainText></TextGroup> Sanitária – Brazil) suggests that the risk factors for <Mark2>C. auris</Mark2> infections are similar to those for infections caused by other Candida species. Diabetes mellitus, the presence of a central venous catheter, immunosuppression, neutropenia, broad-spectrum antibiotic exposure, parenteral nutrition, blood transfusion, hemodialysis, surgery within 30 days, admission to an intensive care unit, antifungal agents received within 30 days, concomitant bacteremia, concomitant candidemia, indwelling urinary catheter, candiduria, chronic kidney disease, and recent chemotherapy are among the 12 risk factors known to date. Patients of all ages, from premature infants to the elderly, have been diagnosed with infections <TextLink reference="16"></TextLink>. More research may be needed to learn more about <Mark2>C. auris</Mark2> infection, including early detection, risk factors, and treatments.</Pgraph><Pgraph>Neutrophils play an important role in the control of invasive fungal infections such as candidiasis. They combat yeasts by phagocytosis or by producing neutrophil extracellular traps (NETs) <TextLink reference="17"></TextLink>. These neutrophils have web-like chromosomal DNA structures decorated with histones and antimicrobial effector molecules such as proteins. Human neutrophils do not recognize <Mark2>C. auris</Mark2>, indicating an innate weakening of the immune response to this yeast <TextLink reference="17"></TextLink>.</Pgraph><Pgraph>According to a study conducted in UK, healthcare spending related to an outbreak of this infection increased by about 10%, owing primarily to prolonged hospitalization time in infected individuals. Expenditures for complementary examinations were also high and persisted long after the infectious outbreak ended <TextLink reference="18"></TextLink>.</Pgraph><SubHeadline>Resistance</SubHeadline><Pgraph>More than 90% of <Mark2>C. auris</Mark2> isolates from clade I and III and about half of the isolates from clade IV are resistant to fluconazole <TextLink reference="12"></TextLink>, <TextLink reference="19"></TextLink>, <TextLink reference="20"></TextLink>. In addition, antifungal resistance against polyenes and echinocandins has been reported in these clades. Typically, clade II isolates are susceptible to azoles and other common antifungals <TextLink reference="21"></TextLink>, <TextLink reference="22"></TextLink>. The detection of multi- or even pan-resistant <TextGroup><Mark2>C. auris</Mark2></TextGroup> strains is alarming <TextLink reference="23"></TextLink>.</Pgraph><SubHeadline>Laboratory characteristic</SubHeadline><Pgraph>The morphology of <Mark2>C. auris</Mark2> may resemble other, more common, <Mark2>Candida</Mark2> spp.; thus, identification based only on colonies is not possible <TextLink reference="24"></TextLink>. Most commercial biochemical tests commonly used may misidentify <Mark2>C. auris</Mark2> <TextLink reference="25"></TextLink>.</Pgraph><Pgraph><Mark2>C. auris</Mark2> is a para-extended ovoid budding yeast that seldom produces pseudohyphae <TextLink reference="26"></TextLink>. This organism can withstand high levels of salinity and heat. <Mark2>C. auris</Mark2> may be distinguished from other <Mark2>Candida</Mark2> species by its ability to grow at temperatures as high as 42°C <TextLink reference="26"></TextLink>. In culture, some strains of <Mark2>C. auris</Mark2> have been shown to form aggregations, which may help the organism resist detergents, ultraviolet radiation, and antimicrobial agents. <Mark2>C. auris</Mark2> creates biofilms, which act as a surface adhesion mechanism <TextLink reference="26"></TextLink>. However, due to the rarity of pseudohyphae, these biofilms are substantially thinner and less complex than those of <Mark2>Candida albicans</Mark2> <TextLink reference="26"></TextLink>.</Pgraph><Pgraph>Mistaken identification as other yeasts may occur when using standard biochemical methods and commercially available tests. Correct identification at the species level requires more advanced techniques, i.e., DNA sequencing or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF), or both <TextLink reference="27"></TextLink>. When invasive non-albicans Candida species are found, infection rates are on the rise, or after patients are admitted from a facility reporting a <Mark2>C. auris</Mark2> epidemic, and if the local laboratory lacks any specialized diagnostic techniques, the only option is clarification by a reference laboratory, where the isolates also are tested for antifungal susceptibility. According to a recent study of the diagnostic capacity of mycology laboratories in Latin America, only 16.6% of the centers in Brazil had this structure, while 15.5% of the centers could perform fungal DNA sequencing (9.5% could do both) <TextLink reference="28"></TextLink>.</Pgraph></TextBlock>
<TextBlock linked="yes" name="Infection control">
<MainHeadline>Infection control</MainHeadline><SubHeadline>Necessity</SubHeadline><Pgraph>The importance of controlling this opportunistic pathogen is due to </Pgraph><Pgraph><UnorderedList><ListItem level="1">high transmissibility <TextLink reference="29"></TextLink>, <TextLink reference="30"></TextLink> and tenacity for <TextGroup><PlainText>4–14 days</PlainText></TextGroup> <TextLink reference="31"></TextLink>, <TextLink reference="32"></TextLink>, <TextLink reference="33"></TextLink></ListItem><ListItem level="1">resistance to several antifungal drugs</ListItem><ListItem level="1">risk of causing bloodstream and other disseminated infections</ListItem><ListItem level="1">propensity to cause outbreaks due to difficult identification</ListItem><ListItem level="1">endangerment of patients with immunosuppression or immunodeficiency, as in the case of Covid-19, HIV or after transplantation.</ListItem></UnorderedList></Pgraph><Pgraph>Prompt notification is essential to implement infection control precautions in a timely manner and to ensure vigilance for development of infections in patients found to be colonized <TextLink reference="34"></TextLink>. The detection of a case of <Mark2>C. auris</Mark2> should trigger an investigation including a detailed case review and screening of close-contact patients for <TextGroup><Mark2>C. auris</Mark2></TextGroup> carriage <TextLink reference="25"></TextLink>, because <Mark2>C. auris</Mark2> is distinguished from other <Mark2>Candida</Mark2> species by its transmissibility and high level of resistance to antifungal medications. </Pgraph><Pgraph>In Germany, it is recommended to send isolated <Mark2>C. auris</Mark2> strains to the National Reference Center for Invasive Fungal Infections in order to record the epidemiological development <TextLink reference="30"></TextLink>.</Pgraph><SubHeadline>Transmission</SubHeadline><Pgraph><Mark2>C. auris</Mark2> is mainly transmitted through contact (hands, medical devices, near-patient environment including walls and floor). The environment may be the principal reservoir of<Mark2> C. auris</Mark2>, with transmission occurring through contaminated surfaces and equipment, such as patient-care equipment (stethoscopes, thermometers, etc.) or direct contact with persons <TextLink reference="30"></TextLink>. Despite infection control measures, the yeast persists and spreads, indicating a resistance to environmental conditions, high transmissibility, and the ability to quickly colonize the patient’s skin and the surrounding environment <TextLink reference="30"></TextLink>. After treating the infection, patients may remain colonized for up to <TextGroup><PlainText>3 months</PlainText></TextGroup> <TextLink reference="30"></TextLink>.</Pgraph><SubHeadline>Infection control measures</SubHeadline><Pgraph>Contact precaution, single room or cohorting of colonized or infected patients as well as pre-emptive isolation of contact patients or enhanced barrier precautions are recommended (Table 1 <ImgLink imgNo="1" imgType="table"/>). As there are currently no established protocols for decolonization and determining when it is safe to end isolation, these precautions need to be applied until discharge from the hospital. Screening (see above) of close contacts of identified cases for <Mark2>C. auris</Mark2> carriage with axilla and groin swabs is important. Other sites (urine, wounds, catheter exit sites, throat etc.) can be sampled, if clinically relevant or indicated.</Pgraph><Pgraph>Hand antisepsis with alcohol-based hand rubs is essential to interrupt cross infections (Table 1 <ImgLink imgNo="1" imgType="table"/>). Chlorhexidine gluconate (CHG) has shown some efficacy <Mark2>in vitro</Mark2>, but there are reports of patients with persistent colonization despite a twice-daily antiseptic body wash with CHG-based products <TextLink reference="35"></TextLink>. Alcohol-based hand rubs are the preferred hand hygiene method for <Mark2>C. auris</Mark2>. If hands are visibly soiled, first wash with soap and water <TextLink reference="36"></TextLink>, dry thoroughly (because wet skin decreases the efficacy of alcohol-based hand rubs) <TextLink reference="37"></TextLink>, and thereafter perform hand antisepsis. The combination of washing and hand antisepsis can be expected to be effective, since in model tests on porcine skin a log reduction of 2.8 was achieved by washing for 30 s and a 3-log reduction using a 30-s rub-in of ethanol-based handgel (75% v/v) <TextLink reference="38"></TextLink>. Wearing gloves is not a substitute for hand hygiene <TextLink reference="36"></TextLink>.</Pgraph><Pgraph>During isolation, daily disinfecting cleaning of the floor and near-patient surfaces is required. After discharge of patients, terminal disinfecting cleaning is necessary <TextLink reference="39"></TextLink>. </Pgraph><Pgraph>Depending of the formulation of the surface disinfectant, QAV may be less effective. The CDC and the ECDC therefore recommend sporocidal surface disinfectants <TextLink reference="34"></TextLink>, <TextLink reference="36"></TextLink> such as oxidants, peracetic acid or chlorine-based disinfectants (i.e. 1,000 ppm sodium hypochlorite). After patient discharge, room disinfection by vaporization with hydrogen peroxide is an effective alternative to traditional wiping. </Pgraph><Pgraph>Analogously, disinfection of reusable equipment (e.g., monitoring devices, thermometers, pulse oximeters, blood pressure measuring instruments, etc.) is performed with sporocidal disinfectans. </Pgraph><Pgraph>Environmental sampling or screening of healthcare workers are not routinely recommended <TextLink reference="36"></TextLink>.</Pgraph></TextBlock>
<TextBlock linked="yes" name="Prevention of spreading from the hospital">
<MainHeadline>Prevention of spreading from the hospital</MainHeadline><Pgraph>In the USA, the detection of <Mark2>C. auris</Mark2> is manditorially nationally notifiable since 2018 <TextLink reference="40"></TextLink>. In Germany, it is legally required that the receiving facility or the general practitioner be informed in the transfer sheet <Mark2>(Überleitungsbogen</Mark2>) on colonization or previous infection with a multidrug-resistant organism (MDRO) or other critical pathogens such as <Mark2>C. auris</Mark2> <TextLink reference="41"></TextLink>.</Pgraph></TextBlock>
<TextBlock linked="yes" name="Antimicrobial stewardship (ABS)">
<MainHeadline>Antimicrobial stewardship (ABS)</MainHeadline><Pgraph>Although there is no evidence for the influence of ABS on the emergence and spread of <Mark2>C. auris</Mark2>, it is likely that an environment with a high level of broad-spectrum antibacterial and antifungal use will select multidrug-resistant yeasts. Therefore, antifungal prophylaxis should be weighed carefully in settings with evidence of <Mark2>C. auris</Mark2> transmission <TextLink reference="34"></TextLink>. Additionally, colonization is not an indication for antifungal treatment, because it does not eradicate <Mark2>C. auris</Mark2> <TextLink reference="16"></TextLink>.</Pgraph><Pgraph>Health surveillance tools are needed to prevent the spread of new diseases globally <TextLink reference="42"></TextLink>.</Pgraph><Pgraph>Immunosuppressive drugs used to treat COVID-19 cases open the door for fungal infections, for instance, with <TextGroup><Mark2>C. auris</Mark2></TextGroup>, which, in combination with the ecological imbalance, is causing novel illnesses in humans (e.g., opportunistic fungal infection) <TextLink reference="43"></TextLink>.</Pgraph><Pgraph>The emergence of antifungal resistance poses another threat to human health and food safety, necessitating the development of novel antifungals <TextLink reference="42"></TextLink>. The β-glucan synthesis inhibitor SCY-078 and rezafungin (previously named CD101) show promise as therapeutic possibilities. Turbinmicin, a chemical generated by a marine microbiome, named after the species from which it was isolated, and <Mark2>Ecteinascidia corneto</Mark2>, are intriguing therapy options. <Mark2>Candida auris</Mark2> and <Mark2>Aspergillus fumigatus</Mark2> were eliminated by this chemical with no negative effects in <Mark2>in vitro</Mark2> and mouse trials <TextLink reference="44"></TextLink>.</Pgraph></TextBlock>
<TextBlock linked="yes" name="Concluding remarks">
<MainHeadline>Concluding remarks</MainHeadline><Pgraph>The widespread use of antifungal drugs, especially of fluconazole (resistance in <Mark2>C. auris</Mark2> in >70%) in ICU patients, deficiencies in standard precautions and delayed diagnosis are the main reasons for outbreaks <TextLink reference="2"></TextLink>. Patients with severe immunosuppression, induced by drugs or illness, and critically ill patients are particularly at risk. In combination with rising ambient temperatures, which might have selected thermotolerant yeasts in wetlands, travelling and spreading through different ecosystems and hosts (e.g., birds), has resulted in an ecological imbalance. Tolerance to high salinity levels and the ability to grow at 42°C argue for the latter hypothesis <TextLink reference="45"></TextLink>, <TextLink reference="46"></TextLink>, <TextLink reference="47"></TextLink>. Presumably, the interaction of all these factors paves the way for novel illnesses caused by opportunistic fungal infections, such as <Mark2>C. auris</Mark2> <TextLink reference="43"></TextLink>. </Pgraph><Pgraph>Health surveillance tools are needed to prevent the spread of new diseases globally <TextLink reference="42"></TextLink>. The analysis of outbreaks in different countries necessitates the development of an efficient strategy to restrict the spread of <Mark2>C. auris</Mark2> in Brazil and other nations that lack the essential infrastructure <TextLink reference="16"></TextLink>. Detection of even a single case of <TextGroup><Mark2>C. auris</Mark2></TextGroup> should trigger an epidemiological investigation of an outbreak <TextLink reference="34"></TextLink> and the immediate start of infection control measures to prevent further spread.</Pgraph></TextBlock>
<TextBlock linked="yes" name="Notes">
<MainHeadline>Notes</MainHeadline><SubHeadline>Competing interests</SubHeadline><Pgraph>The authors declare that they have no competing interests.</Pgraph><SubHeadline>Authors’ ORCID:</SubHeadline><Pgraph><UnorderedList><ListItem level="1">Marcelo Caliman Sato: <Hyperlink href="https://orcid.org/0009-0006-2964-2690">0009-0006-2964-2690</Hyperlink></ListItem><ListItem level="1">Emilene Cristine Izu Nakamura Pietro: <LineBreak></LineBreak><Hyperlink href="https://orcid.org/0000-0002-4113-3980">0000-0002-4113-3980</Hyperlink></ListItem><ListItem level="1">Lucas Marques da Costa Alves: <LineBreak></LineBreak><Hyperlink href="https://orcid.org/0000-0001-9018-6395">0000-0001-9018-6395</Hyperlink></ListItem><ListItem level="1">Axel Kramer: <Hyperlink href="https://orcid.org/0000-0003-4193-2149">0000-0003-4193-2149</Hyperlink></ListItem><ListItem level="1">Paulo Sérgio da Silva Santos: <Hyperlink href="https://orcid.org/0000-0002-0674-3759">0000-0002-0674-3759</Hyperlink></ListItem></UnorderedList></Pgraph></TextBlock>
<References linked="yes">
<Reference refNo="1">
<RefAuthor>Satoh K</RefAuthor>
<RefAuthor>Makimura K</RefAuthor>
<RefAuthor>Hasumi Y</RefAuthor>
<RefAuthor>Nishiyama Y</RefAuthor>
<RefAuthor>Uchida K</RefAuthor>
<RefAuthor>Yamaguchi H</RefAuthor>
<RefTitle>Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital</RefTitle>
<RefYear>2009</RefYear>
<RefJournal>Microbiol Immunol</RefJournal>
<RefPage>41-4</RefPage>
<RefTotal>Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009 Jan;53(1):41-4. DOI: 10.1111/j.1348-0421.2008.00083.x</RefTotal>
<RefLink>https://doi.org/10.1111/j.1348-0421.2008.00083.x</RefLink>
</Reference>
<Reference refNo="2">
<RefAuthor>Meis JF</RefAuthor>
<RefAuthor>Chowdhary A</RefAuthor>
<RefTitle>Candida auris: a global fungal public health threat</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>Lancet Infect Dis</RefJournal>
<RefPage>1298-9</RefPage>
<RefTotal>Meis JF, Chowdhary A. Candida auris: a global fungal public health threat. Lancet Infect Dis. 2018 Dec;18(12):1298-9. DOI: 10.1016/S1473-3099(18)30609-1</RefTotal>
<RefLink>https://doi.org/10.1016/S1473-3099(18)30609-1</RefLink>
</Reference>
<Reference refNo="3">
<RefAuthor>Kohlenberg A</RefAuthor>
<RefAuthor>Struelens MJ</RefAuthor>
<RefAuthor>Monnet DL</RefAuthor>
<RefAuthor>Plachouras D</RefAuthor>
<RefAuthor> Candida auris survey collaborative group</RefAuthor>
<RefTitle>Epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>Euro Surveill</RefJournal>
<RefPage></RefPage>
<RefTotal>Kohlenberg A, Struelens MJ, Monnet DL, Plachouras D; Candida auris survey collaborative group. Epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. Euro Surveill. 2018 Mar;23(13). DOI: 10.2807/1560-7917.ES.2018.23.13.18-00136</RefTotal>
<RefLink>https://doi.org/10.2807/1560-7917.ES.2018.23.13.18-00136</RefLink>
</Reference>
<Reference refNo="4">
<RefAuthor>Hamprecht A</RefAuthor>
<RefAuthor>Barber AE</RefAuthor>
<RefAuthor>Mellinghoff SC</RefAuthor>
<RefAuthor>Thelen P</RefAuthor>
<RefAuthor>Walther G</RefAuthor>
<RefAuthor>Yu Y</RefAuthor>
<RefAuthor>Neurgaonkar P</RefAuthor>
<RefAuthor>Dandekar T</RefAuthor>
<RefAuthor>Cornely OA</RefAuthor>
<RefAuthor>Martin R</RefAuthor>
<RefAuthor>Kurzai O</RefAuthor>
<RefAuthor> German Candida auris Study Group</RefAuthor>
<RefTitle>Candida auris in Germany and Previous Exposure to Foreign Healthcare</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Emerg Infect Dis</RefJournal>
<RefPage>1763-5</RefPage>
<RefTotal>Hamprecht A, Barber AE, Mellinghoff SC, Thelen P, Walther G, Yu Y, Neurgaonkar P, Dandekar T, Cornely OA, Martin R, Kurzai O; German Candida auris Study Group. Candida auris in Germany and Previous Exposure to Foreign Healthcare. Emerg Infect Dis. 2019 Sep;25(9):1763-5. DOI: 10.3201/eid2509.190262</RefTotal>
<RefLink>https://doi.org/10.3201/eid2509.190262</RefLink>
</Reference>
<Reference refNo="5">
<RefAuthor>Pan American Health Organization/World Health Organization (PAHO/WHO)</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2021</RefYear>
<RefBookTitle>Epidemiological alert. Candida auris outbreaks in health care services in the context of the COVID-19 pandemic – 6 February 2021</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Pan American Health Organization/World Health Organization (PAHO/WHO). Epidemiological alert. Candida auris outbreaks in health care services in the context of the COVID-19 pandemic – 6 February 2021. 2021 Feb 6 [Accessed 2023 Jun 7]. Available from: https://www.paho.org/en/documents/epidemiological-alert-candida-auris-outbreaks-health-care-services-context-covid-19</RefTotal>
<RefLink>https://www.paho.org/en/documents/epidemiological-alert-candida-auris-outbreaks-health-care-services-context-covid-19</RefLink>
</Reference>
<Reference refNo="6">
<RefAuthor>Schelenz S</RefAuthor>
<RefAuthor>Hagen F</RefAuthor>
<RefAuthor>Rhodes JL</RefAuthor>
<RefAuthor>Abdolrasouli A</RefAuthor>
<RefAuthor>Chowdhary A</RefAuthor>
<RefAuthor>Hall A</RefAuthor>
<RefAuthor>Ryan L</RefAuthor>
<RefAuthor>Shackleton J</RefAuthor>
<RefAuthor>Trimlett R</RefAuthor>
<RefAuthor>Meis JF</RefAuthor>
<RefAuthor>Armstrong-James D</RefAuthor>
<RefAuthor>Fisher MC</RefAuthor>
<RefTitle>First hospital outbreak of the globally emerging in a European hospital</RefTitle>
<RefYear>2016</RefYear>
<RefJournal>Antimicrob Resist Infect Control</RefJournal>
<RefPage>35</RefPage>
<RefTotal>Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-James D, Fisher MC. First hospital outbreak of the globally emerging in a European hospital. Antimicrob Resist Infect Control. 2016;5:35. DOI: 10.1186/s13756-016-0132-5</RefTotal>
<RefLink>https://doi.org/10.1186/s13756-016-0132-5</RefLink>
</Reference>
<Reference refNo="7">
<RefAuthor>Chen J</RefAuthor>
<RefAuthor>Tian S</RefAuthor>
<RefAuthor>Han X</RefAuthor>
<RefAuthor>Chu Y</RefAuthor>
<RefAuthor>Wang Q</RefAuthor>
<RefAuthor>Zhou B</RefAuthor>
<RefAuthor>Shang H</RefAuthor>
<RefTitle>Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>BMC Infect Dis</RefJournal>
<RefPage>827</RefPage>
<RefTotal>Chen J, Tian S, Han X, Chu Y, Wang Q, Zhou B, Shang H. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. BMC Infect Dis. 2020 Nov;20(1):827. DOI: 10.1186/s12879-020-05543-0</RefTotal>
<RefLink>https://doi.org/10.1186/s12879-020-05543-0</RefLink>
</Reference>
<Reference refNo="8">
<RefAuthor>Centers for Disease Control and Prevention</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2023</RefYear>
<RefBookTitle>Tracking Candida auris</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Centers for Disease Control and Prevention. Tracking Candida auris. 2023 [Accessed 2023 Jun 7]. Available from: https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html</RefTotal>
<RefLink>https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html</RefLink>
</Reference>
<Reference refNo="9">
<RefAuthor>Najeeb H</RefAuthor>
<RefAuthor>Siddiqui SA</RefAuthor>
<RefAuthor>Anas Z</RefAuthor>
<RefAuthor>Ali SH</RefAuthor>
<RefAuthor>Usmani SUR</RefAuthor>
<RefAuthor>Jawed F</RefAuthor>
<RefAuthor>Jatoi HN</RefAuthor>
<RefTitle>The Menace of Epidemic Amidst the COVID-19 Pandemic: A Systematic Review</RefTitle>
<RefYear>2022</RefYear>
<RefJournal>Diseases</RefJournal>
<RefPage></RefPage>
<RefTotal>Najeeb H, Siddiqui SA, Anas Z, Ali SH, Usmani SUR, Jawed F, Jatoi HN. The Menace of Epidemic Amidst the COVID-19 Pandemic: A Systematic Review. Diseases. 2022 Aug;10(3). DOI: 10.3390/diseases10030058</RefTotal>
<RefLink>https://doi.org/10.3390/diseases10030058</RefLink>
</Reference>
<Reference refNo="10">
<RefAuthor>Nobrega de Almeida J Jr</RefAuthor>
<RefAuthor>Brandão IB</RefAuthor>
<RefAuthor>Francisco EC</RefAuthor>
<RefAuthor>de Almeida SLR</RefAuthor>
<RefAuthor>de Oliveira Dias P</RefAuthor>
<RefAuthor>Pereira FM</RefAuthor>
<RefAuthor>Santos Ferreira F</RefAuthor>
<RefAuthor>de Andrade TS</RefAuthor>
<RefAuthor>de Miranda Costa MM</RefAuthor>
<RefAuthor>de Souza Jordão RT</RefAuthor>
<RefAuthor>Meis JF</RefAuthor>
<RefAuthor>Colombo AL</RefAuthor>
<RefAuthor> Candida auris Brazilian Study Group</RefAuthor>
<RefTitle>Axillary Digital Thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>Mycoses</RefJournal>
<RefPage>1062-72</RefPage>
<RefTotal>Nobrega de Almeida J Jr, Brandão IB, Francisco EC, de Almeida SLR, de Oliveira Dias P, Pereira FM, Santos Ferreira F, de Andrade TS, de Miranda Costa MM, de Souza Jordão RT, Meis JF, Colombo AL; Candida auris Brazilian Study Group. Axillary Digital Thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil. Mycoses. 2021 Sep;64(9):1062-72. DOI: 10.1111/myc.13320</RefTotal>
<RefLink>https://doi.org/10.1111/myc.13320</RefLink>
</Reference>
<Reference refNo="11">
<RefAuthor>Lockhart SR</RefAuthor>
<RefAuthor>Etienne KA</RefAuthor>
<RefAuthor>Vallabhaneni S</RefAuthor>
<RefAuthor>Farooqi J</RefAuthor>
<RefAuthor>Chowdhary A</RefAuthor>
<RefAuthor>Govender NP</RefAuthor>
<RefAuthor>Colombo AL</RefAuthor>
<RefAuthor>Calvo B</RefAuthor>
<RefAuthor>Cuomo CA</RefAuthor>
<RefAuthor>Desjardins CA</RefAuthor>
<RefAuthor>Berkow EL</RefAuthor>
<RefAuthor>Castanheira M</RefAuthor>
<RefAuthor>Magobo RE</RefAuthor>
<RefAuthor>Jabeen K</RefAuthor>
<RefAuthor>Asghar RJ</RefAuthor>
<RefAuthor>Meis JF</RefAuthor>
<RefAuthor>Jackson B</RefAuthor>
<RefAuthor>Chiller T</RefAuthor>
<RefAuthor>Litvintseva AP</RefAuthor>
<RefTitle>Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses</RefTitle>
<RefYear>2017</RefYear>
<RefJournal>Clin Infect Dis</RefJournal>
<RefPage>134-40</RefPage>
<RefTotal>Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2017 Jan;64(2):134-40. DOI: 10.1093/cid/ciw691</RefTotal>
<RefLink>https://doi.org/10.1093/cid/ciw691</RefLink>
</Reference>
<Reference refNo="12">
<RefAuthor>Chow NA</RefAuthor>
<RefAuthor>Muñoz JF</RefAuthor>
<RefAuthor>Gade L</RefAuthor>
<RefAuthor>Berkow EL</RefAuthor>
<RefAuthor>Li X</RefAuthor>
<RefAuthor>Welsh RM</RefAuthor>
<RefAuthor>Forsberg K</RefAuthor>
<RefAuthor>Lockhart SR</RefAuthor>
<RefAuthor>Adam R</RefAuthor>
<RefAuthor>Alanio A</RefAuthor>
<RefAuthor>Alastruey-Izquierdo A</RefAuthor>
<RefAuthor>Althawadi S</RefAuthor>
<RefAuthor>Araúz AB</RefAuthor>
<RefAuthor>Ben-Ami R</RefAuthor>
<RefAuthor>Bharat A</RefAuthor>
<RefAuthor>Calvo B</RefAuthor>
<RefAuthor>Desnos-Ollivier M</RefAuthor>
<RefAuthor>Escandón P</RefAuthor>
<RefAuthor>Gardam D</RefAuthor>
<RefAuthor>Gunturu R</RefAuthor>
<RefAuthor>Heath CH</RefAuthor>
<RefAuthor>Kurzai O</RefAuthor>
<RefAuthor>Martin R</RefAuthor>
<RefAuthor>Litvintseva AP</RefAuthor>
<RefAuthor>Cuomo CA</RefAuthor>
<RefTitle>Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>mBio</RefJournal>
<RefPage></RefPage>
<RefTotal>Chow NA, Muñoz JF, Gade L, Berkow EL, Li X, Welsh RM, Forsberg K, Lockhart SR, Adam R, Alanio A, Alastruey-Izquierdo A, Althawadi S, Araúz AB, Ben-Ami R, Bharat A, Calvo B, Desnos-Ollivier M, Escandón P, Gardam D, Gunturu R, Heath CH, Kurzai O, Martin R, Litvintseva AP, Cuomo CA. Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses. mBio. 2020 Apr;11(2). DOI: 10.1128/mBio.03364-19</RefTotal>
<RefLink>https://doi.org/10.1128/mBio.03364-19</RefLink>
</Reference>
<Reference refNo="13">
<RefAuthor>Spruijtenburg B</RefAuthor>
<RefAuthor>Badali H</RefAuthor>
<RefAuthor>Abastabar M</RefAuthor>
<RefAuthor>Mirhendi H</RefAuthor>
<RefAuthor>Khodavaisy S</RefAuthor>
<RefAuthor>Sharifisooraki J</RefAuthor>
<RefAuthor>Taghizadeh Armaki M</RefAuthor>
<RefAuthor>de Groot T</RefAuthor>
<RefAuthor>Meis JF</RefAuthor>
<RefTitle>Confirmation of fifth clade by whole genome sequencing</RefTitle>
<RefYear>2022</RefYear>
<RefJournal>Emerg Microbes Infect</RefJournal>
<RefPage>2405-11</RefPage>
<RefTotal>Spruijtenburg B, Badali H, Abastabar M, Mirhendi H, Khodavaisy S, Sharifisooraki J, Taghizadeh Armaki M, de Groot T, Meis JF. Confirmation of fifth clade by whole genome sequencing. Emerg Microbes Infect. 2022 Dec;11(1):2405-11. DOI: 10.1080/22221751.2022.2125349</RefTotal>
<RefLink>https://doi.org/10.1080/22221751.2022.2125349</RefLink>
</Reference>
<Reference refNo="14">
<RefAuthor>Griffith N</RefAuthor>
<RefAuthor>Danziger L</RefAuthor>
<RefTitle>Urinary Tract Infections and Possible Treatment</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>Antibiotics (Basel)</RefJournal>
<RefPage></RefPage>
<RefTotal>Griffith N, Danziger L. Urinary Tract Infections and Possible Treatment. Antibiotics (Basel). 2020 Dec;9(12). DOI: 10.3390/antibiotics9120898</RefTotal>
<RefLink>https://doi.org/10.3390/antibiotics9120898</RefLink>
</Reference>
<Reference refNo="15">
<RefAuthor>Pathirana RU</RefAuthor>
<RefAuthor>Friedman J</RefAuthor>
<RefAuthor>Norris HL</RefAuthor>
<RefAuthor>Salvatori O</RefAuthor>
<RefAuthor>McCall AD</RefAuthor>
<RefAuthor>Kay J</RefAuthor>
<RefAuthor>Edgerton M</RefAuthor>
<RefTitle>Fluconazole-Resistant Candida auris Is Susceptible to Salivary Histatin 5 Killing and to Intrinsic Host Defenses</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>Antimicrob Agents Chemother</RefJournal>
<RefPage></RefPage>
<RefTotal>Pathirana RU, Friedman J, Norris HL, Salvatori O, McCall AD, Kay J, Edgerton M. Fluconazole-Resistant Candida auris Is Susceptible to Salivary Histatin 5 Killing and to Intrinsic Host Defenses. Antimicrob Agents Chemother. 2018 Feb;62(2). DOI: 10.1128/AAC.01872-17</RefTotal>
<RefLink>https://doi.org/10.1128/AAC.01872-17</RefLink>
</Reference>
<Reference refNo="16">
<RefAuthor>Associação Mineira de Epidemiologia e Controle de Infecções</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2022</RefYear>
<RefBookTitle>Nota técnica GVIMS/GGTES/ANVISA Nº 9/2022. Orientações para identificação, prevenção e controle de infecções por Candida auris em serviços de saúde</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Associação Mineira de Epidemiologia e Controle de Infecções. Nota técnica GVIMS/GGTES/ANVISA Nº 9/2022. Orientações para identificação, prevenção e controle de infecções por Candida auris em serviços de saúde. 2022 Sep 16 [Accessed 2023 Jun 7]. Available from: https://ameci.org.br/orientacoes-para-identificacao-prevencao-e-controle-de-infeccoes-por-candida-auris-em-servicos-de-saude-3/</RefTotal>
<RefLink>https://ameci.org.br/orientacoes-para-identificacao-prevencao-e-controle-de-infeccoes-por-candida-auris-em-servicos-de-saude-3/</RefLink>
</Reference>
<Reference refNo="17">
<RefAuthor>El Baradei A</RefAuthor>
<RefTitle>A decade after the emergence of Candida auris: what do we know?</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>Eur J Clin Microbiol Infect Dis</RefJournal>
<RefPage>1617-27</RefPage>
<RefTotal>El Baradei A. A decade after the emergence of Candida auris: what do we know? Eur J Clin Microbiol Infect Dis. 2020 Sep;39(9):1617-27. DOI: 10.1007/s10096-020-03886-9</RefTotal>
<RefLink>https://doi.org/10.1007/s10096-020-03886-9</RefLink>
</Reference>
<Reference refNo="18">
<RefAuthor>Taori SK</RefAuthor>
<RefAuthor>Khonyongwa K</RefAuthor>
<RefAuthor>Hayden I</RefAuthor>
<RefAuthor>Athukorala GDA</RefAuthor>
<RefAuthor>Letters A</RefAuthor>
<RefAuthor>Fife A</RefAuthor>
<RefAuthor>Desai N</RefAuthor>
<RefAuthor>Borman AM</RefAuthor>
<RefTitle>Candida auris outbreak: Mortality, interventions and cost of sustaining control</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>J Infect</RefJournal>
<RefPage>601-11</RefPage>
<RefTotal>Taori SK, Khonyongwa K, Hayden I, Athukorala GDA, Letters A, Fife A, Desai N, Borman AM. Candida auris outbreak: Mortality, interventions and cost of sustaining control. J Infect. 2019 Dec;79(6):601-11. DOI: 10.1016/j.jinf.2019.09.007</RefTotal>
<RefLink>https://doi.org/10.1016/j.jinf.2019.09.007</RefLink>
</Reference>
<Reference refNo="19">
<RefAuthor>Chowdhary A</RefAuthor>
<RefAuthor>Prakash A</RefAuthor>
<RefAuthor>Sharma C</RefAuthor>
<RefAuthor>Kordalewska M</RefAuthor>
<RefAuthor>Kumar A</RefAuthor>
<RefAuthor>Sarma S</RefAuthor>
<RefAuthor>Tarai B</RefAuthor>
<RefAuthor>Singh A</RefAuthor>
<RefAuthor>Upadhyaya G</RefAuthor>
<RefAuthor>Upadhyay S</RefAuthor>
<RefAuthor>Yadav P</RefAuthor>
<RefAuthor>Singh PK</RefAuthor>
<RefAuthor>Khillan V</RefAuthor>
<RefAuthor>Sachdeva N</RefAuthor>
<RefAuthor>Perlin DS</RefAuthor>
<RefAuthor>Meis JF</RefAuthor>
<RefTitle>A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>J Antimicrob Chemother</RefJournal>
<RefPage>891-9</RefPage>
<RefTotal>Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, Tarai B, Singh A, Upadhyaya G, Upadhyay S, Yadav P, Singh PK, Khillan V, Sachdeva N, Perlin DS, Meis JF. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018 Apr;73(4):891-9. DOI: 10.1093/jac/dkx480</RefTotal>
<RefLink>https://doi.org/10.1093/jac/dkx480</RefLink>
</Reference>
<Reference refNo="20">
<RefAuthor>Lockhart SR</RefAuthor>
<RefTitle>Candida auris and multidrug resistance: Defining the new normal</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Fungal Genet Biol</RefJournal>
<RefPage>103243</RefPage>
<RefTotal>Lockhart SR. Candida auris and multidrug resistance: Defining the new normal. Fungal Genet Biol. 2019 Oct;131:103243. DOI: 10.1016/j.fgb.2019.103243</RefTotal>
<RefLink>https://doi.org/10.1016/j.fgb.2019.103243</RefLink>
</Reference>
<Reference refNo="21">
<RefAuthor>Sekizuka T</RefAuthor>
<RefAuthor>Iguchi S</RefAuthor>
<RefAuthor>Umeyama T</RefAuthor>
<RefAuthor>Inamine Y</RefAuthor>
<RefAuthor>Makimura K</RefAuthor>
<RefAuthor>Kuroda M</RefAuthor>
<RefAuthor>Miyazaki Y</RefAuthor>
<RefAuthor>Kikuchi K</RefAuthor>
<RefTitle>Clade II Candida auris possess genomic structural variations related to an ancestral strain</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>PLoS One</RefJournal>
<RefPage>e0223433</RefPage>
<RefTotal>Sekizuka T, Iguchi S, Umeyama T, Inamine Y, Makimura K, Kuroda M, Miyazaki Y, Kikuchi K. Clade II Candida auris possess genomic structural variations related to an ancestral strain. PLoS One. 2019;14(10):e0223433. DOI: 10.1371/journal.pone.0223433</RefTotal>
<RefLink>https://doi.org/10.1371/journal.pone.0223433</RefLink>
</Reference>
<Reference refNo="22">
<RefAuthor>Kwon YJ</RefAuthor>
<RefAuthor>Shin JH</RefAuthor>
<RefAuthor>Byun SA</RefAuthor>
<RefAuthor>Choi MJ</RefAuthor>
<RefAuthor>Won EJ</RefAuthor>
<RefAuthor>Lee D</RefAuthor>
<RefAuthor>Lee SY</RefAuthor>
<RefAuthor>Chun S</RefAuthor>
<RefAuthor>Lee JH</RefAuthor>
<RefAuthor>Choi HJ</RefAuthor>
<RefAuthor>Kee SJ</RefAuthor>
<RefAuthor>Kim SH</RefAuthor>
<RefAuthor>Shin MG</RefAuthor>
<RefTitle>Candida auris Clinical Isolates from South Korea: Identification, Antifungal Susceptibility, and Genotyping</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>J Clin Microbiol</RefJournal>
<RefPage></RefPage>
<RefTotal>Kwon YJ, Shin JH, Byun SA, Choi MJ, Won EJ, Lee D, Lee SY, Chun S, Lee JH, Choi HJ, Kee SJ, Kim SH, Shin MG. Candida auris Clinical Isolates from South Korea: Identification, Antifungal Susceptibility, and Genotyping. J Clin Microbiol. 2019 Apr;57(4). DOI: 10.1128/JCM.01624-18</RefTotal>
<RefLink>https://doi.org/10.1128/JCM.01624-18</RefLink>
</Reference>
<Reference refNo="23">
<RefAuthor>Ademe M</RefAuthor>
<RefAuthor>Girma F</RefAuthor>
<RefTitle>From Multidrug Resistance to Pan-Resistant Strains</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>Infect Drug Resist</RefJournal>
<RefPage>1287-94</RefPage>
<RefTotal>Ademe M, Girma F. From Multidrug Resistance to Pan-Resistant Strains. Infect Drug Resist. 2020;13:1287-94. DOI: 10.2147/IDR.S249864</RefTotal>
<RefLink>https://doi.org/10.2147/IDR.S249864</RefLink>
</Reference>
<Reference refNo="24">
<RefAuthor>Cortegiani A</RefAuthor>
<RefAuthor>Misseri G</RefAuthor>
<RefAuthor>Fasciana T</RefAuthor>
<RefAuthor>Giammanco A</RefAuthor>
<RefAuthor>Giarratano A</RefAuthor>
<RefAuthor>Chowdhary A</RefAuthor>
<RefTitle>Epidemiology, clinical characteristics, resistance, and treatment of infections by</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>J Intensive Care</RefJournal>
<RefPage>69</RefPage>
<RefTotal>Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by. J Intensive Care. 2018;6:69. DOI: 10.1186/s40560-018-0342-4</RefTotal>
<RefLink>https://doi.org/10.1186/s40560-018-0342-4</RefLink>
</Reference>
<Reference refNo="25">
<RefAuthor>Centers for Disease Control and Prevention (CDC)</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2022</RefYear>
<RefBookTitle>Procedure for collection of patient swabs</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Centers for Disease Control and Prevention (CDC). Procedure for collection of patient swabs. 2022 [Accessed 2023 Jun 7]. Available from: https://www.cdc.gov/fungal/candida-auris/c-auris-patient-swab.html</RefTotal>
<RefLink>https://www.cdc.gov/fungal/candida-auris/c-auris-patient-swab.html</RefLink>
</Reference>
<Reference refNo="26">
<RefAuthor>Jeffery-Smith A</RefAuthor>
<RefAuthor>Taori SK</RefAuthor>
<RefAuthor>Schelenz S</RefAuthor>
<RefAuthor>Jeffery K</RefAuthor>
<RefAuthor>Johnson EM</RefAuthor>
<RefAuthor>Borman A</RefAuthor>
<RefAuthor> Candida auris Incident Management Team</RefAuthor>
<RefAuthor>Manuel R</RefAuthor>
<RefAuthor>Brown CS</RefAuthor>
<RefTitle>Candida auris: a Review of the Literature</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>Clin Microbiol Rev</RefJournal>
<RefPage></RefPage>
<RefTotal>Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A; Candida auris Incident Management Team, Manuel R, Brown CS. Candida auris: a Review of the Literature. Clin Microbiol Rev. 2018 Jan;31(1). DOI: 10.1128/CMR.00029-17</RefTotal>
<RefLink>https://doi.org/10.1128/CMR.00029-17</RefLink>
</Reference>
<Reference refNo="27">
<RefAuthor>Fasciana T</RefAuthor>
<RefAuthor>Cortegiani A</RefAuthor>
<RefAuthor>Ippolito M</RefAuthor>
<RefAuthor>Giarratano A</RefAuthor>
<RefAuthor>Di Quattro O</RefAuthor>
<RefAuthor>Lipari D</RefAuthor>
<RefAuthor>Graceffa D</RefAuthor>
<RefAuthor>Giammanco A</RefAuthor>
<RefTitle>An Overview of How to Screen, Detect, Test and Control This Emerging Pathogen</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>Antibiotics (Basel)</RefJournal>
<RefPage></RefPage>
<RefTotal>Fasciana T, Cortegiani A, Ippolito M, Giarratano A, Di Quattro O, Lipari D, Graceffa D, Giammanco A. An Overview of How to Screen, Detect, Test and Control This Emerging Pathogen. Antibiotics (Basel). 2020 Nov;9(11). DOI: 10.3390/antibiotics9110778</RefTotal>
<RefLink>https://doi.org/10.3390/antibiotics9110778</RefLink>
</Reference>
<Reference refNo="28">
<RefAuthor>Pasqualotto AC</RefAuthor>
<RefAuthor>Sukiennik TCT</RefAuthor>
<RefAuthor>Meis JF</RefAuthor>
<RefTitle>Brazil is so far free from Candida auris. Are we missing something?</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Braz J Infect Dis</RefJournal>
<RefPage>149-50</RefPage>
<RefTotal>Pasqualotto AC, Sukiennik TCT, Meis JF. Brazil is so far free from Candida auris. Are we missing something? Braz J Infect Dis. 2019;23(3):149-50. DOI: 10.1016/j.bjid.2019.05.004</RefTotal>
<RefLink>https://doi.org/10.1016/j.bjid.2019.05.004</RefLink>
</Reference>
<Reference refNo="34">
<RefAuthor>European Centre for Disease Prevention and Control</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2018</RefYear>
<RefBookTitle>Candida auris in Healthcare Settings – Europe. First Update, 23 April 2018</RefBookTitle>
<RefPage></RefPage>
<RefTotal>European Centre for Disease Prevention and Control. Candida auris in Healthcare Settings–Europe – First Update, 23 April 2018. Stockholm: ECDC; 2018 [Accessed 2023 Jun 7]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-Candida-auris-European-Union-countries-first-update.pdf</RefTotal>
<RefLink>https://www.ecdc.europa.eu/sites/default/files/documents/RRA-Candida-auris-European-Union-countries-first-update.pdf</RefLink>
</Reference>
<Reference refNo="29">
<RefAuthor>Agência Nacional de Vigilância Sanitária – Anvisa</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2020</RefYear>
<RefBookTitle>Alerta de Risco GVIMS/GGTES/Anvisa no 01/2020</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Agência Nacional de Vigilância Sanitária – Anvisa. Alerta de Risco GVIMS/GGTES/Anvisa no 01/2020. 2020 Dec 07 [Accessed 2023 Jun 7]. Available from: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/comunicados-de-risco-1/alerta-01-2020-candida-auris-07-12-2020.pdf/view</RefTotal>
<RefLink>https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/comunicados-de-risco-1/alerta-01-2020-candida-auris-07-12-2020.pdf/view</RefLink>
</Reference>
<Reference refNo="30">
<RefAuthor>Wagener J</RefAuthor>
<RefAuthor>Kurzai O</RefAuthor>
<RefTitle>Candida auris – Steckbrief eines neuen Pilzes</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Dt Ärztebl Suppl. Perspektiven der Infektiologie & Immunologie</RefJournal>
<RefPage>29-30</RefPage>
<RefTotal>Wagener J, Kurzai O. Candida auris – Steckbrief eines neuen Pilzes. Dt Ärztebl Suppl. Perspektiven der Infektiologie & Immunologie. 2019;116(1):29-30.</RefTotal>
</Reference>
<Reference refNo="31">
<RefAuthor>Piedrahita CT</RefAuthor>
<RefAuthor>Cadnum JL</RefAuthor>
<RefAuthor>Jencson AL</RefAuthor>
<RefAuthor>Shaikh AA</RefAuthor>
<RefAuthor>Ghannoum MA</RefAuthor>
<RefAuthor>Donskey CJ</RefAuthor>
<RefTitle>Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species</RefTitle>
<RefYear>2017</RefYear>
<RefJournal>Infect Control Hosp Epidemiol</RefJournal>
<RefPage>1107-9</RefPage>
<RefTotal>Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of Candida auris and Other Candida Species. Infect Control Hosp Epidemiol. 2017 Sep;38(9):1107-9. DOI: 10.1017/ice.2017.127</RefTotal>
<RefLink>https://doi.org/10.1017/ice.2017.127</RefLink>
</Reference>
<Reference refNo="32">
<RefAuthor>Welsh RM</RefAuthor>
<RefAuthor>Bentz ML</RefAuthor>
<RefAuthor>Shams A</RefAuthor>
<RefAuthor>Houston H</RefAuthor>
<RefAuthor>Lyons A</RefAuthor>
<RefAuthor>Rose LJ</RefAuthor>
<RefAuthor>Litvintseva AP</RefAuthor>
<RefTitle>Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface</RefTitle>
<RefYear>2017</RefYear>
<RefJournal>J Clin Microbiol</RefJournal>
<RefPage>2996-3005</RefPage>
<RefTotal>Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, Litvintseva AP. Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface. J Clin Microbiol. 2017 Oct;55(10):2996-3005. DOI: 10.1128/JCM.00921-17</RefTotal>
<RefLink>https://doi.org/10.1128/JCM.00921-17</RefLink>
</Reference>
<Reference refNo="33">
<RefAuthor>Short B</RefAuthor>
<RefAuthor>Brown J</RefAuthor>
<RefAuthor>Delaney C</RefAuthor>
<RefAuthor>Sherry L</RefAuthor>
<RefAuthor>Williams C</RefAuthor>
<RefAuthor>Ramage G</RefAuthor>
<RefAuthor>Kean R</RefAuthor>
<RefTitle>Candida auris exhibits resilient biofilm characteristics in vitro: implications for environmental persistence</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>J Hosp Infect</RefJournal>
<RefPage>92-6</RefPage>
<RefTotal>Short B, Brown J, Delaney C, Sherry L, Williams C, Ramage G, Kean R. Candida auris exhibits resilient biofilm characteristics in vitro: implications for environmental persistence. J Hosp Infect. 2019 Sep;103(1):92-6. DOI: 10.1016/j.jhin.2019.06.006</RefTotal>
<RefLink>https://doi.org/10.1016/j.jhin.2019.06.006</RefLink>
</Reference>
<Reference refNo="35">
<RefAuthor>Ku TSN</RefAuthor>
<RefAuthor>Walraven CJ</RefAuthor>
<RefAuthor>Lee SA</RefAuthor>
<RefTitle>Disinfectants and Implications for Infection Control</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>Front Microbiol</RefJournal>
<RefPage>726</RefPage>
<RefTotal>Ku TSN, Walraven CJ, Lee SA. Disinfectants and Implications for Infection Control. Front Microbiol. 2018;9:726. DOI: 10.3389/fmicb.2018.00726</RefTotal>
<RefLink>https://doi.org/10.3389/fmicb.2018.00726</RefLink>
</Reference>
<Reference refNo="36">
<RefAuthor>Centers for Disease Control and Prevention (CDC)</RefAuthor>
<RefTitle></RefTitle>
<RefYear></RefYear>
<RefBookTitle>Infection Prevention and Control for Candida auris</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Centers for Disease Control and Prevention (CDC). Infection Prevention and Control for Candida auris [Accessed 2023 Jun 7]. Available from: https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html</RefTotal>
<RefLink>https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html</RefLink>
</Reference>
<Reference refNo="37">
<RefAuthor>Hübner NO</RefAuthor>
<RefAuthor>Kampf G</RefAuthor>
<RefAuthor>Kamp P</RefAuthor>
<RefAuthor>Kohlmann T</RefAuthor>
<RefAuthor>Kramer A</RefAuthor>
<RefTitle>Does a preceding hand wash and drying time after surgical hand disinfection influence the efficacy of a propanol-based hand rub?</RefTitle>
<RefYear>2006</RefYear>
<RefJournal>BMC Microbiol</RefJournal>
<RefPage>57</RefPage>
<RefTotal>Hübner NO, Kampf G, Kamp P, Kohlmann T, Kramer A. Does a preceding hand wash and drying time after surgical hand disinfection influence the efficacy of a propanol-based hand rub? BMC Microbiol. 2006 Jun;6:57. DOI: 10.1186/1471-2180-6-57</RefTotal>
<RefLink>https://doi.org/10.1186/1471-2180-6-57</RefLink>
</Reference>
<Reference refNo="38">
<RefAuthor>Fu L</RefAuthor>
<RefAuthor>Le T</RefAuthor>
<RefAuthor>Liu Z</RefAuthor>
<RefAuthor>Wang L</RefAuthor>
<RefAuthor>Guo H</RefAuthor>
<RefAuthor>Yang J</RefAuthor>
<RefAuthor>Chen Q</RefAuthor>
<RefAuthor>Hu J</RefAuthor>
<RefTitle>Different efficacies of common disinfection methods against candida auris and other candida species</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>J Infect Public Health</RefJournal>
<RefPage>730-6</RefPage>
<RefTotal>Fu L, Le T, Liu Z, Wang L, Guo H, Yang J, Chen Q, Hu J. Different efficacies of common disinfection methods against candida auris and other candida species. J Infect Public Health. 2020 May;13(5):730-6. DOI: 10.1016/j.jiph.2020.01.008</RefTotal>
<RefLink>https://doi.org/10.1016/j.jiph.2020.01.008</RefLink>
</Reference>
<Reference refNo="48">
<RefAuthor>Public Health England</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2016</RefYear>
<RefBookTitle>Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Public Health England. Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris. 2016 Jun [Accessed2023 Jun 7]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/532117/Guidance-candida-auris.pdf</RefTotal>
<RefLink>https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/532117/Guidance-candida-auris.pdf</RefLink>
</Reference>
<Reference refNo="39">
<RefAuthor>Ling M</RefAuthor>
<RefAuthor> International Society for Infectious disease</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2018</RefYear>
<RefBookTitle>Guide to Infection Control in tThe Healthcare Setting</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Ling M; International Society for Infectious disease. Guide to Infection Control in tThe Healthcare Setting. 2018 Apr [Accessed 2023 Jun 7]. Available from: https://isid.org/wp-content/uploads/2019/07/ISID_GUIDE_FUNGI.pdf</RefTotal>
<RefLink>https://isid.org/wp-content/uploads/2019/07/ISID_GUIDE_FUNGI.pdf</RefLink>
</Reference>
<Reference refNo="49">
<RefAuthor>Centers for Disease Control and Prevention (CDC)</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2022</RefYear>
<RefBookTitle>Implementation of Personal Protective Equipment (PPE) Use in Nursing Homes to Prevent Spread of Multidrug-resistant Organisms (MDROs)</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Centers for Disease Control and Prevention (CDC). Implementation of Personal Protective Equipment (PPE) Use in Nursing Homes to Prevent Spread of Multidrug-resistant Organisms (MDROs). 2022 [Accessed 2023 Jun 7]. Available from: https://www.cdc.gov/hai/containment/PPE-Nursing-Homes.html</RefTotal>
<RefLink>https://www.cdc.gov/hai/containment/PPE-Nursing-Homes.html</RefLink>
</Reference>
<Reference refNo="40">
<RefAuthor>Centers for Disease Control and Prevention (CDC)</RefAuthor>
<RefTitle></RefTitle>
<RefYear></RefYear>
<RefBookTitle>Candida auris 2023 Case Definition</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Centers for Disease Control and Prevention (CDC). Candida auris 2023 Case Definition. Available from: https://ndc.services.cdc.gov/case-definitions/candida-auris-2023/</RefTotal>
<RefLink>https://ndc.services.cdc.gov/case-definitions/candida-auris-2023/</RefLink>
</Reference>
<Reference refNo="41">
<RefAuthor>Anonym</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2022</RefYear>
<RefBookTitle>Infektionsschutzgesetz vom 20. Juli 2000 (BGBl I S. 1045), zuletzt durch Artikel 8b des Gesetzes vom 20. Dezember 2022 (BGBl I S. 2793) geändert</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Infektionsschutzgesetz vom 20. Juli 2000 (BGBl I S. 1045), zuletzt durch Artikel 8b des Gesetzes vom 20. Dezember 2022 (BGBl I S. 2793) geändert. Verfügbar unter: https://www.gesetze-im-internet.de/ifsg/IfSG.pdf</RefTotal>
<RefLink>https://www.gesetze-im-internet.de/ifsg/IfSG.pdf</RefLink>
</Reference>
<Reference refNo="42">
<RefAuthor>Rhodes J</RefAuthor>
<RefAuthor>Fisher MC</RefAuthor>
<RefTitle>Global epidemiology of emerging Candida auris</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Curr Opin Microbiol</RefJournal>
<RefPage>84-9</RefPage>
<RefTotal>Rhodes J, Fisher MC. Global epidemiology of emerging Candida auris. Curr Opin Microbiol. 2019 Dec;52:84-9. DOI: 10.1016/j.mib.2019.05.008</RefTotal>
<RefLink>https://doi.org/10.1016/j.mib.2019.05.008</RefLink>
</Reference>
<Reference refNo="43">
<RefAuthor>Sarma S</RefAuthor>
<RefAuthor>Upadhyay S</RefAuthor>
<RefTitle>Current perspective on emergence, diagnosis and drug resistance in Candida auris</RefTitle>
<RefYear>2017</RefYear>
<RefJournal>Infect Drug Resist</RefJournal>
<RefPage>155-65</RefPage>
<RefTotal>Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155-65. DOI: 10.2147/IDR.S116229</RefTotal>
<RefLink>https://doi.org/10.2147/IDR.S116229</RefLink>
</Reference>
<Reference refNo="44">
<RefAuthor>Zhang F</RefAuthor>
<RefAuthor>Zhao M</RefAuthor>
<RefAuthor>Braun DR</RefAuthor>
<RefAuthor>Ericksen SS</RefAuthor>
<RefAuthor>Piotrowski JS</RefAuthor>
<RefAuthor>Nelson J</RefAuthor>
<RefAuthor>Peng J</RefAuthor>
<RefAuthor>Ananiev GE</RefAuthor>
<RefAuthor>Chanana S</RefAuthor>
<RefAuthor>Barns K</RefAuthor>
<RefAuthor>Fossen J</RefAuthor>
<RefAuthor>Sanchez H</RefAuthor>
<RefAuthor>Chevrette MG</RefAuthor>
<RefAuthor>Guzei IA</RefAuthor>
<RefAuthor>Zhao C</RefAuthor>
<RefAuthor>Guo L</RefAuthor>
<RefAuthor>Tang W</RefAuthor>
<RefAuthor>Currie CR</RefAuthor>
<RefAuthor>Rajski SR</RefAuthor>
<RefAuthor>Audhya A</RefAuthor>
<RefAuthor>Andes DR</RefAuthor>
<RefAuthor>Bugni TS</RefAuthor>
<RefTitle>A marine microbiome antifungal targets urgent-threat drug-resistant fungi</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>Science</RefJournal>
<RefPage>974-8</RefPage>
<RefTotal>Zhang F, Zhao M, Braun DR, Ericksen SS, Piotrowski JS, Nelson J, Peng J, Ananiev GE, Chanana S, Barns K, Fossen J, Sanchez H, Chevrette MG, Guzei IA, Zhao C, Guo L, Tang W, Currie CR, Rajski SR, Audhya A, Andes DR, Bugni TS. A marine microbiome antifungal targets urgent-threat drug-resistant fungi. Science. 2020 Nov;370(6519):974-8. DOI: 10.1126/science.abd6919</RefTotal>
<RefLink>https://doi.org/10.1126/science.abd6919</RefLink>
</Reference>
<Reference refNo="45">
<RefAuthor>Jackson BR</RefAuthor>
<RefAuthor>Chow N</RefAuthor>
<RefAuthor>Forsberg K</RefAuthor>
<RefAuthor>Litvintseva AP</RefAuthor>
<RefAuthor>Lockhart SR</RefAuthor>
<RefAuthor>Welsh R</RefAuthor>
<RefAuthor>Vallabhaneni S</RefAuthor>
<RefAuthor>Chiller T</RefAuthor>
<RefTitle>On the Origins of a Species: What Might Explain the Rise of?</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>J Fungi (Basel)</RefJournal>
<RefPage></RefPage>
<RefTotal>Jackson BR, Chow N, Forsberg K, Litvintseva AP, Lockhart SR, Welsh R, Vallabhaneni S, Chiller T. On the Origins of a Species: What Might Explain the Rise of? J Fungi (Basel). 2019 Jul;5(3). DOI: 10.3390/jof5030058</RefTotal>
<RefLink>https://doi.org/10.3390/jof5030058</RefLink>
</Reference>
<Reference refNo="46">
<RefAuthor>Casadevall A</RefAuthor>
<RefAuthor>Kontoyiannis DP</RefAuthor>
<RefAuthor>Robert V</RefAuthor>
<RefTitle>On the Emergence of Candida auris: Climate Change, Azoles, Swamps, and Birds</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>mBio</RefJournal>
<RefPage></RefPage>
<RefTotal>Casadevall A, Kontoyiannis DP, Robert V. On the Emergence of Candida auris: Climate Change, Azoles, Swamps, and Birds. mBio. 2019 Jul;10(4). DOI: 10.1128/mBio.01397-19</RefTotal>
<RefLink>https://doi.org/10.1128/mBio.01397-19</RefLink>
</Reference>
<Reference refNo="47">
<RefAuthor>Misseri G</RefAuthor>
<RefAuthor>Ippolito M</RefAuthor>
<RefAuthor>Cortegiani A</RefAuthor>
<RefTitle>Global warming “heating up” the ICU through Candida auris infections: the climate changes theory</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Crit Care</RefJournal>
<RefPage>416</RefPage>
<RefTotal>Misseri G, Ippolito M, Cortegiani A. Global warming “heating up” the ICU through Candida auris infections: the climate changes theory. Crit Care. 2019 Dec;23(1):416. DOI: 10.1186/s13054-019-2702-4</RefTotal>
<RefLink>https://doi.org/10.1186/s13054-019-2702-4</RefLink>
</Reference>
</References>
<Media>
<Tables>
<Table format="png">
<MediaNo>1</MediaNo>
<MediaID>1</MediaID>
<Caption><Pgraph><Mark1>Table 1: Summarized recommendations from infection control societies [7, 29, 36, 39, 40, 41] for infection control of </Mark1><Mark1><Mark2>C. auris</Mark2></Mark1></Pgraph></Caption>
</Table>
<NoOfTables>1</NoOfTables>
</Tables>
<Figures>
<NoOfPictures>0</NoOfPictures>
</Figures>
<InlineFigures>
<NoOfPictures>0</NoOfPictures>
</InlineFigures>
<Attachments>
<NoOfAttachments>0</NoOfAttachments>
</Attachments>
</Media>
</OrigData>
</GmsArticle>]]></plaintext></textgroup></pgraph></textblock></origdata></gmsarticle>